Page 1 | Search Results | Blood Advances | American Society of Hematology

1-20 of 86

Sort by

Sort Order Select

Journal Articles

The potential role of protease systems in hemophilic arthropathy

Wayne W. S. Hauw, Joanne S. J. Chia, Harshal H. Nandurkar, Maithili Sashindranath

Blood Adv (2022) 6 (18): 5505–5515.

https://doi.org/10.1182/bloodadvances.2022007028

Published: 2022

Journal Articles

International consensus statement on the management of cardiovascular risk of Bruton’s tyrosine kinase inhibitors in CLL

Farrukh T. Awan, Daniel Addison, Feras Alfraih, Sergio J. Baratta, Rodrigo Noronha Campos, María Silvana Cugliari, Yeow Tee Goh, Valery Alexandrovich Ionin, Stefanie Mundnich, Aaron L. Sverdlov, Constantine Tam, Loïc Ysebaert

Blood Adv (2022) 6 (18): 5516–5525.

https://doi.org/10.1182/bloodadvances.2022007938

Published: 2022

Includes: Supplemental data

Journal Articles

Bite-size introduction to canine hematologic malignancies

Matthew J. Atherton, Nicola J. Mason

Blood Adv (2022) 6 (13): 4073–4084.

https://doi.org/10.1182/bloodadvances.2021005045

Published: 2022

Journal Articles

Post–hematopoietic stem cell transplantation immune-mediated anemia: a literature review and novel therapeutics

Yazan Migdady, Yifan Pang, Shelley S. Kalsi, Richard Childs, Sally Arai

Blood Adv (2022) 6 (8): 2707–2721.

https://doi.org/10.1182/bloodadvances.2021006279

Published: 2022

Journal Articles

Clinical features, pathophysiology, and therapy of poor graft function post–allogeneic stem cell transplantation

Ashvind Prabahran, Rachel Koldej, Lynette Chee, David Ritchie

Blood Adv (2022) 6 (6): 1947–1959.

https://doi.org/10.1182/bloodadvances.2021004537

Published: 2022

Journal Articles

Juvenile myelomonocytic leukemia in the molecular era: a clinician’s guide to diagnosis, risk stratification, and treatment

Astrid Wintering, Christopher C. Dvorak, Elliot Stieglitz, Mignon L. Loh

Blood Adv (2021) 5 (22): 4783–4793.

https://doi.org/10.1182/bloodadvances.2021005117

Published: 2021

Journal Articles

PARP1 as a therapeutic target in acute myeloid leukemia and myelodysplastic syndrome

Christina-Nefeli Kontandreopoulou, Panagiotis T. Diamantopoulos, Despina Tiblalexi, Nefeli Giannakopoulou, Nora-Athina Viniou

Blood Adv (2021) 5 (22): 4794–4805.

https://doi.org/10.1182/bloodadvances.2021004638

Published: 2021

Journal Articles

Gut microbiome in pediatric acute leukemia: from predisposition to cure

Riccardo Masetti, Edoardo Muratore, Davide Leardini, Daniele Zama, Silvia Turroni, Patrizia Brigidi, Susanna Esposito, Andrea Pession

Blood Adv (2021) 5 (22): 4619–4629.

https://doi.org/10.1182/bloodadvances.2021005129

Published: 2021

Journal Articles

Population pharmacokinetic modeling of factor concentrates in hemophilia: an overview and evaluation of best practice

Tine M. H. J. Goedhart, Laura H. Bukkems, C. Michel Zwaan, Ron A. A. Mathôt, Marjon H. Cnossen, for the OPTI-CLOT study group and SYMPHONY consortium

Blood Adv (2021) 5 (20): 4314–4325.

https://doi.org/10.1182/bloodadvances.2021005096

Published: 2021

Journal Articles

Follicular lymphoma and macrophages: impact of approved and novel therapies

Sushanth Gouni, Mario L. Marques-Piubelli, Paolo Strati

Blood Adv (2021) 5 (20): 4303–4312.

https://doi.org/10.1182/bloodadvances.2021005722

Published: 2021

Journal Articles

Adoptive T-cell therapy for Hodgkin lymphoma

Carrie Ho, Marco Ruella, Bruce L. Levine, Jakub Svoboda

Blood Adv (2021) 5 (20): 4291–4302.

https://doi.org/10.1182/bloodadvances.2021005304

Published: 2021

Journal Articles

Canonical Wnt: a safeguard and threat for erythropoiesis

Rosa A. Krimpenfort, Micha Nethe

Blood Adv (2021) 5 (18): 3726–3735.

https://doi.org/10.1182/bloodadvances.2021004845

Published: 2021

Journal Articles

The promise and perils of immunotherapy

Stefanie Lesch, Saar Gill

Blood Adv (2021) 5 (18): 3709–3725.

https://doi.org/10.1182/bloodadvances.2021004453

Published: 2021

Journal Articles

Approach to the diagnosis of aplastic anemia

Amy E. DeZern, Jane E. Churpek

Blood Adv (2021) 5 (12): 2660–2671.

https://doi.org/10.1182/bloodadvances.2021004345

Published: 2021

Journal Articles

The potential of proliferative and apoptotic parameters in clinical flow cytometry of myeloid malignancies

Stefan G. C. Mestrum, Anton H. N. Hopman, Frans C. S. Ramaekers, Math P. G. Leers

Blood Adv (2021) 5 (7): 2040–2052.

https://doi.org/10.1182/bloodadvances.2020004094

Published: 2021

Journal Articles

Immunotherapy perspectives in the new era of B-cell editing

Natsuko Ueda, Marine Cahen, Yannic Danger, Jérôme Moreaux, Christophe Sirac, Michel Cogné

Blood Adv (2021) 5 (6): 1770–1779.

https://doi.org/10.1182/bloodadvances.2020003792

Published: 2021

Journal Articles

Platelets as drivers of ischemia/reperfusion injury after stroke

Noor F. Shaik, Raymond F. Regan, Ulhas P. Naik

Blood Adv (2021) 5 (5): 1576–1584.

https://doi.org/10.1182/bloodadvances.2020002888

Published: 2021

Journal Articles

Kinase inhibitors developed for treatment of hematologic malignancies: implications for immune modulation in COVID-19

Chaja F. Jacobs, Eric Eldering, Arnon P. Kater

Blood Adv (2021) 5 (3): 913–925.

https://doi.org/10.1182/bloodadvances.2020003768

Published: 2021

Includes: Supplemental data

Journal Articles

Overcoming resistance to targeted therapies in chronic lymphocytic leukemia

Sigrid S. Skånland, Anthony R. Mato

Blood Adv (2021) 5 (1): 334–343.

https://doi.org/10.1182/bloodadvances.2020003423

Published: 2021

Journal Articles

Application of machine learning in the management of acute myeloid leukemia: current practice and future prospects

Jan-Niklas Eckardt, Martin Bornhäuser, Karsten Wendt, Jan Moritz Middeke

Blood Adv (2020) 4 (23): 6077–6085.

https://doi.org/10.1182/bloodadvances.2020002997

Published: 2020

NARROW

The potential role of protease systems in hemophilic arthropathy

International consensus statement on the management of cardiovascular risk of Bruton’s tyrosine kinase inhibitors in CLL

Bite-size introduction to canine hematologic malignancies

Post–hematopoietic stem cell transplantation immune-mediated anemia: a literature review and novel therapeutics

Clinical features, pathophysiology, and therapy of poor graft function post–allogeneic stem cell transplantation

Juvenile myelomonocytic leukemia in the molecular era: a clinician’s guide to diagnosis, risk stratification, and treatment

PARP1 as a therapeutic target in acute myeloid leukemia and myelodysplastic syndrome

Gut microbiome in pediatric acute leukemia: from predisposition to cure

Population pharmacokinetic modeling of factor concentrates in hemophilia: an overview and evaluation of best practice

Follicular lymphoma and macrophages: impact of approved and novel therapies

Adoptive T-cell therapy for Hodgkin lymphoma

Canonical Wnt: a safeguard and threat for erythropoiesis

The promise and perils of immunotherapy

Approach to the diagnosis of aplastic anemia

The potential of proliferative and apoptotic parameters in clinical flow cytometry of myeloid malignancies

Immunotherapy perspectives in the new era of B-cell editing

Platelets as drivers of ischemia/reperfusion injury after stroke

Kinase inhibitors developed for treatment of hematologic malignancies: implications for immune modulation in COVID-19

Overcoming resistance to targeted therapies in chronic lymphocytic leukemia

Application of machine learning in the management of acute myeloid leukemia: current practice and future prospects

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only